BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36274112)

  • 1. CD44
    Sihombing UHM; Andrijono A; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
    J Egypt Natl Canc Inst; 2022 Oct; 34(1):44. PubMed ID: 36274112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of CD44
    Sihombing UHM; Andrijono ; Purwoto G; Gandamihardja S; Harahap AR; Rustamadji P; Kekalih A; Widyawati R; Fuady DR
    Gynecol Oncol Rep; 2022 Aug; 42():101005. PubMed ID: 35707599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma.
    Feharsal Y; Andrijono A; Singoprawiro CS; Lisnawati L; Pakasi TA; Putra AD; Kusuma F; Anggraeni TD; Erlina E; Sarwanti S; Mardhiyah T
    Asian Pac J Cancer Prev; 2024 Feb; 25(2):513-519. PubMed ID: 38415537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunodetection of cells with a CD44+/CD24- phenotype in canine mammary neoplasms.
    Magalhães GM; Terra EM; de Oliveira Vasconcelos R; de Barros Bandarra M; Moreira PR; Rosolem MC; Alessi AC
    BMC Vet Res; 2013 Oct; 9():205. PubMed ID: 24119896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of cancer stem cell markers CD24, EPHA1 and CD9 and their correlation with clinical outcome in epithelial ovarian tumours.
    Nagare RP; Sneha S; Sidhanth C; Roopa S; Murhekar K; Shirley S; Swaminathan R; Sridevi V; Ganesan TS
    Cancer Biomark; 2020; 28(3):397-408. PubMed ID: 32224528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET overexpression in ovarian cancer via CD24-induced downregulation of miR-181a: A signalling for cellular quiescence-like state and chemoresistance in ovarian CSCs.
    Kwon JE; Jang Y; Yun BS; Kang S; Kim YH; Kim BG; Cho NH
    Cell Prolif; 2024 May; 57(5):e13582. PubMed ID: 38030594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD24+CD44+CD54+EpCAM+ gastric cancer stem cells predict tumor progression and metastasis: clinical and experimental evidence.
    Gómez-Gallegos AA; Ramírez-Vidal L; Becerril-Rico J; Pérez-Islas E; Hernandez-Peralta ZJ; Toledo-Guzmán ME; García-Carrancá A; Langley E; Hernández-Guerrero A; López-Casillas F; Herrera-Goepfert R; Oñate-Ocaña LF; Ortiz-Sánchez E
    Stem Cell Res Ther; 2023 Feb; 14(1):16. PubMed ID: 36737794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD44 as a cancer stem cell marker and its prognostic value in patients with ovarian carcinoma.
    Bartakova A; Michalova K; Presl J; Vlasak P; Kostun J; Bouda J
    J Obstet Gynaecol; 2018 Jan; 38(1):110-114. PubMed ID: 28816557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Significance of CD44 and CD24 as cancer stem cell markers: an enduring ambiguity.
    Jaggupilli A; Elkord E
    Clin Dev Immunol; 2012; 2012():708036. PubMed ID: 22693526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unraveling the roles of CD44/CD24 and ALDH1 as cancer stem cell markers in tumorigenesis and metastasis.
    Li W; Ma H; Zhang J; Zhu L; Wang C; Yang Y
    Sci Rep; 2017 Oct; 7(1):13856. PubMed ID: 29062075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma.
    Bonneau C; Rouzier R; Geyl C; Cortez A; Castela M; Lis R; Daraï E; Touboul C
    Gynecol Oncol; 2015 Jan; 136(1):112-20. PubMed ID: 25449309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44+ CD24(-) prostate cells are early cancer progenitor/stem cells that provide a model for patients with poor prognosis.
    Hurt EM; Kawasaki BT; Klarmann GJ; Thomas SB; Farrar WL
    Br J Cancer; 2008 Feb; 98(4):756-65. PubMed ID: 18268494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD44+/CD24- ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival.
    Meng E; Long B; Sullivan P; McClellan S; Finan MA; Reed E; Shevde L; Rocconi RP
    Clin Exp Metastasis; 2012 Dec; 29(8):939-48. PubMed ID: 22610780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Prognostic Value of Cancer Stem Cell Markers (CSCs) Expression-ALDH1A1, CD133, CD44-For Survival and Long-Term Follow-Up of Ovarian Cancer Patients.
    Izycka N; Rucinski M; Andrzejewska M; Szubert S; Nowak-Markwitz E; Sterzynska K
    Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
    Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
    J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Cdk2 kinase activity selectively targets the CD44⁺/CD24⁻/Low stem-like subpopulation and restores chemosensitivity of SUM149PT triple-negative breast cancer cells.
    Opyrchal M; Salisbury JL; Iankov I; Goetz MP; McCubrey J; Gambino MW; Malatino L; Puccia G; Ingle JN; Galanis E; D'Assoro AB
    Int J Oncol; 2014 Sep; 45(3):1193-9. PubMed ID: 24970653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD44 and CD24 cannot act as cancer stem cell markers in human lung adenocarcinoma cell line A549.
    Roudi R; Madjd Z; Ebrahimi M; Samani FS; Samadikuchaksaraei A
    Cell Mol Biol Lett; 2014 Mar; 19(1):23-36. PubMed ID: 24363164
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis.
    Durko L; Wlodarski W; Stasikowska-Kanicka O; Wagrowska-Danilewicz M; Danilewicz M; Hogendorf P; Strzelczyk J; Malecka-Panas E
    Dis Markers; 2017; 2017():3276806. PubMed ID: 28659655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD24 expression is a marker for predicting clinical outcome and regulates the epithelial-mesenchymal transition in ovarian cancer via both the Akt and ERK pathways.
    Nakamura K; Terai Y; Tanabe A; Ono YJ; Hayashi M; Maeda K; Fujiwara S; Ashihara K; Nakamura M; Tanaka Y; Tanaka T; Tsunetoh S; Sasaki H; Ohmichi M
    Oncol Rep; 2017 Jun; 37(6):3189-3200. PubMed ID: 28440503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD44/CD24 expression in recurrent gastric cancer: a retrospective analysis.
    Yong CS; Ou Yang CM; Chou YH; Liao CS; Lee CW; Lee CC
    BMC Gastroenterol; 2012 Jul; 12():95. PubMed ID: 22839505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.